Trial Profile
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0777 (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Dec 2014 New trial record